PriceTargets.com logo

Silk Road Medical - SILK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $49.33
  • Forecasted Upside: 5.98 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$46.55 As of 10/3/2022 01:00 AM ET
▲ +1.55 (3.44%)

This chart shows the closing price for SILK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Silk Road Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SILK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SILK

Analyst Price Target is $49.33
▲ +5.98% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Silk Road Medical in the last 3 months. The average price target is $49.33, with a high forecast of $66.00 and a low forecast of $33.00. The average price target represents a 5.98% upside from the last price of $46.55.

This chart shows the closing price for SILK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Silk Road Medical. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/18/2022Stifel NicolausLower Target$55.00 ➝ $46.00Low
7/11/2022CitigroupDowngradeNeutral ➝ Sell$33.00N/A
5/17/2022CitigroupLower Target$44.00 ➝ $33.00N/A
4/5/2022Wolfe ResearchInitiated CoverageOutperform$48.00Low
4/4/2022Piper SandlerBoost TargetNeutral$38.00 ➝ $43.00Medium
2/25/2022CitigroupLower TargetNeutral$45.00 ➝ $37.00High
2/25/2022Piper SandlerLower Target$48.00 ➝ $38.00High
1/3/2022Piper SandlerLower Target$55.00 ➝ $48.00Low
11/22/2021ArgusLower TargetBuy$70.00 ➝ $60.00High
11/19/2021CitigroupUpgradeSell ➝ Neutral$50.00Medium
11/10/2021SVB LeerinkLower TargetOutperform$75.00 ➝ $66.00High
10/1/2021CitigroupDowngradeNeutral ➝ Sell$50.00Medium
7/30/2021Piper SandlerLower TargetNeutral$58.00 ➝ $55.00High
7/20/2021SVB LeerinkReiterated RatingOutperformHigh
3/2/2021CitigroupLower Target$64.00 ➝ $59.00High
11/11/2020Piper SandlerBoost TargetNeutral$54.00 ➝ $58.00Medium
10/12/2020SVB LeerinkBoost TargetOutperform$60.00 ➝ $75.00Low
10/1/2020CitigroupDowngradeBuy ➝ Neutral$58.00 ➝ $71.00High
8/21/2020Piper SandlerInitiated CoverageNeutral$54.00High
8/6/2020Stifel NicolausBoost TargetBuy$47.00 ➝ $55.00High
8/6/2020SVB LeerinkBoost TargetOutperform$51.00 ➝ $60.00Medium
8/6/2020CitigroupBoost TargetBuy$50.00 ➝ $58.00Medium
7/9/2020SVB LeerinkInitiated CoverageOutperform$51.00High
7/1/2020Stifel NicolausReiterated RatingBuy$47.00Low
5/27/2020CitigroupInitiated CoverageBuy$50.00High
5/1/2020Stifel NicolausBoost TargetBuy$37.00 ➝ $47.00Low
2/27/2020Stifel NicolausBoost TargetBuy$49.00 ➝ $51.00High
8/20/2019ArgusInitiated CoverageBuy$52.00 ➝ $52.00Low
4/29/2019Bank of AmericaInitiated CoverageNeutral ➝ Neutral$43.00Medium
4/29/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$45.00Low
4/29/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$44.00Low
4/29/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$40.01Low
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/5/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/4/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/3/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Silk Road Medical logo
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Read More

Today's Range

Now: $46.55
Low: $43.86
High: $46.97

50 Day Range

MA: $44.01
Low: $38.79
High: $49.20

52 Week Range

Now: $46.55
Low: $27.21
High: $63.22

Volume

336,854 shs

Average Volume

312,051 shs

Market Capitalization

$1.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Silk Road Medical?

The following sell-side analysts have issued research reports on Silk Road Medical in the last year: Argus, Citigroup Inc., Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, and Wolfe Research.
View the latest analyst ratings for SILK.

What is the current price target for Silk Road Medical?

6 Wall Street analysts have set twelve-month price targets for Silk Road Medical in the last year. Their average twelve-month price target is $49.33, suggesting a possible upside of 6.0%. SVB Leerink LLC has the highest price target set, predicting SILK will reach $66.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $33.00 for Silk Road Medical in the next year.
View the latest price targets for SILK.

What is the current consensus analyst rating for Silk Road Medical?

Silk Road Medical currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SILK, but not buy more shares or sell existing shares.
View the latest ratings for SILK.

What other companies compete with Silk Road Medical?

Other companies that are similar to Silk Road Medical include Nevro, Embecta, AtriCure, PROCEPT BioRobotics and Beauty Health. Learn More about companies similar to Silk Road Medical.

How do I contact Silk Road Medical's investor relations team?

Silk Road Medical's physical mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company's listed phone number is (408) 720-9002 and its investor relations email address is [email protected] The official website for Silk Road Medical is www.silkroadmed.com. Learn More about contacing Silk Road Medical investor relations.